RankAlpha logo
Back to Rankings

OKUR

OnKure TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Timely progress toward two distinct IND submissions, backed by the reported cash runway, could improve confidence in the pipeline. This remains a development-stage thesis, not a demonstrated efficacy thesis.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Neither OKI-355 nor OKI-345 has patient-level safety or efficacy evidence in the supplied materials; planned IND submissions can slip or draw regulatory questions.
Momentum
43
Value
56
Sentiment
29
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.00 · Bull $3.80 · Bear $1.10Analysis 2026-10-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-09 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $15.50
Why
Momentum43 · Δ7d -
Value56 · Δ7d -0.0
Sentiment29 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Value remains the lead driver in the composite, 7D delta -0.0.

Contradictions & invalidation

  • • Neither OKI-355 nor OKI-345 has patient-level safety or efficacy evidence in the supplied materials; planned IND submissions can slip or draw regulatory questions.
  • • R&D expense was $12.6 million in second-quarter 2026; the runway estimate depends on future spending and development plans [#SEC-8K-2026-08-04].
  • • IND delays, regulatory questions or higher development spending could weigh heavily on a small-cap stock before clinical evidence emerges.

Catalyst clock

2027-06-30

Planned OKI-355 IND submission

Lead driver: Value · See fundamentals
Momentum
43
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
56
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.7
Sentiment
29
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade D. Momentum 42.9 / Value 56.4 / Sentiment 29.5

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-09. Scenario method

B+
Bull case
0%
Probability
Target price
$3.80
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
Most likely
B
Base case
0%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$1.10
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$102.05M
Beta
0.47
Shares Out
40.5M
P/E (TTM) · Derived
-0.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.85
Rev YoY
-
EPS YoY
-73.0%
Gross Margin
-
Op Margin
-
Net Debt
-$58.5M
Current Ratio
26.75
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data